MedPath

Potassium

Generic Name
Potassium
Drug Type
Small Molecule
Chemical Formula
K
CAS Number
7440-09-7
Unique Ingredient Identifier
RWP5GA015D
Background

Potassium is an essential nutrient, like Calcium and Magnesium. It was identified as a shortfall nutrient by the 2015-2020 Advisory Committee of Dietary Guidelines for Americans. Many conditions and diseases interfere with normal body potassium balance, and underconsumption of potassium is one example. Hypokalemia (low potassium) or hyperkalemia (high potassium) may result, manifesting as various signs and symptoms. Some examples of potassium-related complications include life-threatening arrhythmia, neuromuscular dysfunction, diarrhea, nausea, and vomiting.

Various pharmacological preparations have been formulated to replenish potassium. They are available in an assortment of tablet, injection, and other forms, depending on the setting and condition being treated. Potassium is often a key ingredient for intravenous fluids, given to patients in clinical settings for rehydration, nutrition, and replenishment of electrolytes. Examples of potassium formulations include potassium citrate, potassium chloride, and potassium with dextrose and sodium chloride.

Indication

General uses of potassium

Potassium is indicated to treat a variety of conditions. Firstly, it used to replenish potassium that has been depleted by conditions including but not limited to malabsorption, decreased intake, or excess sodium intake. The causes of potassium deficiency are numerous. The following indications for potassium are not comprehensive, but include the main indications for which this nutrient is used. Various products and preparations contain potassium.

Potassium chloride

Potassium chloride is one of the main preparations of potassium used in a clinical setting. The oral solution is indicated for the prevention and treatment of hypokalemia presenting with or without metabolic alkalosis, in patients who have failed conservative management with potassium-rich foods or diuretic dose titrations. The injection form of potassium chloride is indicated to replenish potassium in patients who are not feasible candidates for oral potassium. Highly concentrated potassium is intended for the treatment of potassium deficiency in fluid restricted individuals who cannot tolerate fluid volumes normally associated with injected potassium solutions that contain lower concentrations.

Finally, the extended-release tablet preparation of potassium chloride is used to treat hypokalemia with or without metabolic alkalosis, to treat digitalis intoxication, and to manage patients with hypokalemic familial periodic paralysis. It is also used in the prevention of hypokalemia in those who are at a high risk of negative clinical outcomes if hypokalemia occurs; patients on digitalis or those with cardiac arrhythmias would be at particular risk of negative outcomes.

Potassium chloride with dextrose and sodium chloride

This liquid preparation is is indicated in a clinical setting as a source of water, calories and electrolytes. Potassium acetate solution is meant as an alternative to potassium chloride, replenishing potassium and added to large volume infusion fluids for intravenous injection.

Potassium citrate

The potassium citrate preparation is used for the management of renal tubular acidosis (RTA) with calcium stones (nephrolithiasis); calcium oxalate stones by any cause, and uric acid nephrolithiasis (with or without calcium stones). This regimen also includes adequate water intake (leading to a urine out put of 2 L/day or more) and sodium restriction.

Associated Conditions
Caloric Intake, Electrolyte and fluid balance conditions, Hydration, Hypokalemia, Potassium

Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial of 10 and 14 Days

First Posted Date
2021-05-25
Last Posted Date
2021-05-25
Lead Sponsor
Shandong University
Target Recruit Count
1300
Registration Number
NCT04901117
Locations
🇨🇳

Qilu hosipital, Jinan, Shandong, China

Rifabutin-containing Triple Therapy for Treatment of Helicobacter Pylori

Not Applicable
Completed
Conditions
Helicobacter Pylori Infection
Interventions
First Posted Date
2021-05-10
Last Posted Date
2022-11-15
Lead Sponsor
Shanghai Jiao Tong University School of Medicine
Target Recruit Count
413
Registration Number
NCT04879992
Locations
🇨🇳

Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai, China

Comparative Study Between Nicorandil and Nifedipine for the Treatment of Preterm Labour

Phase 2
Conditions
Preterm Labor With Preterm Delivery
Interventions
First Posted Date
2021-04-15
Last Posted Date
2021-04-15
Lead Sponsor
Ain Shams University
Target Recruit Count
230
Registration Number
NCT04846621
Locations
🇪🇬

Manella Fayez Zaki Beshara, Egypt, Alexandria, Egypt

Effect of Glutathione vs KI in Reducing SDF Staining When Used in Treatment of Primary Carious Teeth

Not Applicable
Conditions
Discoloration, Tooth
Interventions
First Posted Date
2021-03-25
Last Posted Date
2021-04-01
Lead Sponsor
Cairo University
Target Recruit Count
60
Registration Number
NCT04816487

The Impact of Air Travel on Passenger Cognitive Functions

Phase 2
Conditions
Air Travel
Interventions
Drug: Cytochrome C6
Drug: Sodium Chloride Oral Product
Drug: Sodium Citrate Oral Product
Drug: Dextrose Oral Tablet, Chewable
Drug: Probiotic Formula
First Posted Date
2021-03-17
Last Posted Date
2021-03-17
Lead Sponsor
Dinara Zhumanbayeva
Target Recruit Count
50
Registration Number
NCT04802785

A Study of Vonoprazan in Adults With Helicobacter Pylori

First Posted Date
2021-02-15
Last Posted Date
2023-08-31
Lead Sponsor
Takeda
Target Recruit Count
44
Registration Number
NCT04753437
Locations
🇨🇳

West China Hospital, Sichuan University, Phase I Unit, Chengdu, Sichuan, China

Potassium Canrenoate in Brain-dead Organ Donors: Randomized Controlled Clinical Trial

Phase 2
Active, not recruiting
Conditions
Brain-dead Organ Donors
Interventions
Drug: IV Sodium Chloride 0.9 %
First Posted Date
2021-01-19
Last Posted Date
2024-08-23
Lead Sponsor
Central Hospital, Nancy, France
Target Recruit Count
36
Registration Number
NCT04714710
Locations
🇫🇷

CHRU de NANCY, Nancy, France

Bismuth-Metronidazole Triple Therapy for H. Pylori First-line Treatment

Phase 4
Conditions
Helicobacter Pylori Infection
Interventions
First Posted Date
2020-12-14
Last Posted Date
2020-12-22
Lead Sponsor
Shanghai Zhongshan Hospital
Target Recruit Count
270
Registration Number
NCT04667299
Locations
🇨🇳

Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China

Rescue Therapy for Helicobacter Pylori Eradication Treatment

Phase 4
Completed
Conditions
Helicobacter Pylori Infection
Interventions
Drug: Tetracycline,Metronidazole
Drug: Minocycline,Metronidazole
First Posted Date
2020-08-28
Last Posted Date
2024-12-30
Lead Sponsor
Shanghai Jiao Tong University School of Medicine
Target Recruit Count
368
Registration Number
NCT04531059
Locations
🇨🇳

Shanghai East Hospital, Tongji University School of Medicine, Shanghai, Shanghai, China

🇨🇳

Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai, China

🇨🇳

The Second Affiliated Hospital of Zhejiang University school of Medicine, Hangzhou, Zhejiang, China

Outcome of Esmolol Potassium Cardioplegia Compared to Potassium Cardioplegia in Patients With Solitary Valvular Disease; Randomized Controlled Study

Not Applicable
Conditions
Cardioplegia Solution Adverse Reaction
Interventions
First Posted Date
2020-03-13
Last Posted Date
2020-03-13
Lead Sponsor
Kasr El Aini Hospital
Target Recruit Count
80
Registration Number
NCT04306913
Locations
🇪🇬

Kasr alainy medical school, Cairo, Egypt

© Copyright 2025. All Rights Reserved by MedPath